More MS news articles for June 2001

NetGenics is Partner of Schering AG to Build Comprehensive Corporate Gene Database

http://uk.biz.yahoo.com/010611/183/bus2e.html

Monday June 11, 02:04 PM

CLEVELAND--(BW HealthWire)--June 11, 2001--NetGenics, Inc. (Cleveland, OH) is chosen as partner of Schering AG, Berlin, Germany (FSE:SCH; NYSE:SHR), to build a comprehensive corporate gene database for the company on a worldwide basis.
The database will be used to integrate gene data across the Schering Group, including e.g. Berlex Laboratories, Inc., the US-subsidiary of Schering AG. The aim is to provide a single, central point of access to curated and annotated gene data, sequence data, and expression data. Terms of the agreement were not disclosed.

Utilizing proprietary technology from the NetGenics Component Library such as scientific datamarts, bioinformatics software components, and query engines, as well as IBM's DiscoveryLink technology, NetGenics is building a custom gene data integration solution for Schering AG. The system will be used by hundreds of scientists around the world. As a central location for gene data, the system will support collaboration, data sharing, and will provide easy access to proprietary and public gene resource databases.

"In our global research organization we generate and store proprietary data at different research sites", said Prof. Bjorn Wallmark, Head of Corporate Research at Schering AG. "In the process of optimizing our research information management systems we have, together with NetGenics, developed an integrated corporate gene database solution that allows our scientists around the globe to enhance the speed and competitiveness of their target identification and validation efforts".

"Traditional bioinformatics client/vendor relationships involve a large product sale with customization support. This doesn't work with the speed and flexibility requirements these companies have today. NetGenics' Solution Development approach offers sophisticated technical and scientific expertise, starting with a clean-slate definition of the client's needs and problems and leveraging whichever technologies are available and appropriate to address those particular needs" noted Manuel J. Glynias, NetGenics President and CEO.

"The genomics industry is facing an urgency to develop systems that help access and analyze genomic data in a uniform way," said Richard Resnick, Vice President of Solutions Development for NetGenics. "Schering AG has a unique set of needs and we're excited about working with them to help solve their specific problems. This project represents an important development effort for NetGenics, as it allows us to bring our considerable software and scientific component-base to bear on a distinct customer need."

NetGenics, Inc., (www.NetGenics.com) is a privately held company that builds integrated informatics solutions for the life science industry. Its solutions leverage a combination of proprietary software and tailored integration services. NetGenics was established in 1996 and is headquartered in Cleveland, Ohio.

Schering AG (www.schering.de) is a research-based pharmaceutical company. Its activities are focused on four business areas: Fertility Control and Hormone Therapy, Diagnostics and Radio-pharmaceuticals, Dermatology as well as Therapeutics for disabling diseases, e.g. multiple sclerosis, leukemia and solid tumors. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network with external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life.

Statements in the press release that are not descriptions of historical facts are forward-looking and are subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including risks relating to development and commercialization of NetGenics' products and uncertainties relating to NetGenics' dependence on third parties, including corporate partners.

Contact:

NetGenics, Inc., Cleveland
Michael Bush, 216/861-4007
Fax: 216/861-4777
Email: mbush@netgenics.com
www.NetGenics.com